Therapy Detail

Therapy Name KW-2450
Therapy Description

KW-2450 is a multitargeted kinase inhibitor with activity against Aurora A and B, and IGF-1R, which potentially results in decreased tumor cell growth (PMID: 26443806).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
KW-2450 Aurka Inhibitors 23 Aurkb Inhibitors 17 IGF-1R Inhibitor 17 KW-2450 is a multitargeted kinase inhibitor with activity against Aurora A and B, and IGF-1R, which potentially results in decreased tumor cell growth (PMID: 26443806).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown triple-receptor negative breast cancer not applicable KW-2450 Preclinical Actionable In a preclinical study, KW-2450 inhibited the growth of triple-negative breast cancer cells in culture and in xenograft models (PMID: 26443806). 26443806
Unknown unknown breast cancer not applicable KW-2450 Preclinical Actionable In a preclinical study, KW-2450 inhibited growth of several breast cancer cell lines in culture, including ESR1 positive, ERBB2 (HER2) positive/ESR1 positive, ERBB2 (HER2) positive, and triple-negative subtypes (PMID: 26443806). 26443806
Unknown unknown Advanced Solid Tumor not applicable KW-2450 Phase I Actionable In a Phase I trial, 40% (4/10) of patients with advanced solid tumors demonstrated stable disease when treated with KW-2450 (PMID: 26850678). 26850678
Clinical Trial Phase Therapies Title Recruitment Status